cancer immunotherapy

IN8bio showcases gamma-delta T cell advances and glioblastoma survival data at May 2026 R&D Day and major medical conferences.

Nanobiotix presented preclinical data showing its Nanoprimer platform reduces liver toxicity and improves bioavailability of LNP-delivered DNA immunotherapies in mouse models.

Evaxion's AI-Immunology platform identifies endogenous retroviruses as glioblastoma vaccine targets, addressing mutational burden challenges. Results presented at AACR in April 2026.

Epitopea appoints Dr. Lisa Butterfield, immuno-oncology expert, to Scientific Advisory Board to advance RNA-based cancer immunotherapies.

Trogenix publishes Nature data showing 83% complete tumor elimination in aggressive brain cancer model. Phase I/II trial dosing planned for Q2 2026.

Werewolf Therapeutics seeks strategic alternatives including potential sale or merger. Company reports improved 2025 financials, reduced losses, and $57.1M cash reserves.

Global ELISpot & FluoroSpot assay market to grow at 7.1% CAGR through 2031, driven by immunology research and personalized therapies.

Mestag Therapeutics closes $40M financing and appoints leadership to advance FAP-targeted cancer immunotherapy MST-0312 into Phase 1 clinical trials.

Over 40 companies develop 50+ CTLA-4 inhibitor candidates for cancer immunotherapy. Recent FDA approvals and focus on combination strategies drive pipeline expansion.

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.